601 1.25mg
SSGJ-601-CRVO-II-01
Phase 2 small_molecule completed
Quick answer
601 1.25mg for Central Retinal Vein Occlusion is a Phase 2 program (small_molecule) at Sunshine Biopharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sunshine Biopharma
- Indication
- Central Retinal Vein Occlusion
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed